Kalaris Therapeutics, Inc. (KLRS NASDAQ) stock market data APIs
$3.4053
0(0%)
as of September 11, 2026
Try our APIs with
free plan!
Kalaris Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
Prev. Close
3.4053
Open
3.4062
High
3.4062
Low
3.2855
52 wk Range
3.03-11.88
Market Cap
80 461 K
Shares Outstanding
23 805 K
EPS
-0.48
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kalaris Therapeutics, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kalaris Therapeutics, Inc. data using free add-ons & libraries
Get Kalaris Therapeutics, Inc. Fundamental Data
Kalaris Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -46 139 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Kalaris Therapeutics, Inc. Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-11
- EPS/Forecast: -0.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kalaris Therapeutics, Inc. News
New
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) Stockholders
STAMFORD, Conn., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Kalaris Therapeutics, Inc. (Nasdaq: KLRS), formerly AlloVir...
Kalaris appoints Liisa Bayko as CFO
* Kalaris Therapeutics (KLRS [https://seekingalpha.com/symbol/KLRS]) has appointed Liisa Bayko as chief financial officer, the company said on Monday. * Bayko brings more than two decades of expe...
Kalaris Therapeutics Reports Positive Phase 1a Results For TH103 In Neovascular AMD
(RTTNews) - Kalaris Therapeutics, Inc. (KLRS), a clinical-stage biopharmaceutical company focused on retinal diseases, announced encouraging additional data from its Phase 1a single ascending dose tri...
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts Enrollment in the Phase 1b/2 multiple-ascending dose...
Get Kalaris Therapeutics, Inc. fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
